Cargando…

Ex vivo modulation of intact tumor fragments with anti-PD-1 and anti-CTLA-4 influences the expansion and specificity of tumor-infiltrating lymphocytes

Checkpoint inhibition (CPI) therapy and adoptive cell therapy with autologous tumor-infiltrating lymphocytes (TIL-based ACT) are the two most effective immunotherapies for the treatment of metastatic melanoma. While CPI has been the dominating therapy in the past decade, TIL-based ACT is beneficial...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hulen, Thomas Morgan, Friese, Christina, Kristensen, Nikolaj Pagh, Granhøj, Joachim Stoltenborg, Borch, Troels Holz, Peeters, Marlies J. W., Donia, Marco, Andersen, Mads Hald, Hadrup, Sine Reker, Svane, Inge Marie, Met, Özcan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10285209/ https://www.ncbi.nlm.nih.gov/pubmed/37359554 http://dx.doi.org/10.3389/fimmu.2023.1180997

Ejemplares similares

CTLA-4 blockade boosts the expansion of tumor-reactive CD8(+) tumor-infiltrating lymphocytes in ovarian cancer
por: Friese, Christina, et al.
Publicado: (2020)

Adoptive cell therapy with autologous tumor infiltrating lymphocytes and low-dose Interleukin-2 in metastatic melanoma patients
por: Ellebaek, Eva, et al.
Publicado: (2012)

T cell therapy in combination with Vemurafenib in BRAF mutated metastatic melanoma patients
por: Borch, Troels Holz, et al.
Publicado: (2014)

The antigen specific composition of melanoma tumor infiltrating lymphocytes?
por: Hadrup, Sine Reker
Publicado: (2012)

Future role for adoptive T-cell therapy in checkpoint inhibitor-resistant metastatic melanoma
por: Borch, Troels Holz, et al.
Publicado: (2020)

Adoptive cell therapy with tumor infiltrating lymphocytes and intermediate dose IL-2 for metastatic melanoma
por: Andersen, Rikke, et al.
Publicado: (2014)

Broadening the repertoire of melanoma-associated T-cell epitopes
por: Frøsig, Thomas Mørch, et al.
Publicado: (2015)

“Immunotherapy of cancer: present status and future promise”: Danish Cancer Society Symposium, Copenhagen, Denmark, 23rd–25th September 2013
por: Donia, Marco, et al.
Publicado: (2014)

Neoantigen-reactive CD8(+) T cells affect clinical outcome of adoptive cell therapy with tumor-infiltrating lymphocytes in melanoma
por: Kristensen, Nikolaj Pagh, et al.
Publicado: (2022)

Effects of Ipilimumab on expanded tumor infiltrating lymphocytes in patients with stage IV malignant melanoma
por: Bjørn, Jon, et al.
Publicado: (2013)

Tumor-Infiltrating T Cells From Clear Cell Renal Cell Carcinoma Patients Recognize Neoepitopes Derived From Point and Frameshift Mutations
por: Hansen, Ulla Kring, et al.
Publicado: (2020)

Depletion of T lymphocytes is correlated with response to temozolomide in melanoma patients
por: Iversen, Trine Zeeberg, et al.
Publicado: (2013)

Correction: Influence of ipilimumab on expanded tumour derived T cells from patients with metastatic melanoma
por: Bjoern, Jon, et al.
Publicado: (2018)

Influence of ipilimumab on expanded tumour derived T cells from patients with metastatic melanoma
por: Bjoern, Jon, et al.
Publicado: (2017)

Effector CD4 and CD8 T Cells and Their Role in the Tumor Microenvironment
por: Hadrup, Sine, et al.
Publicado: (2012)

First in man study: Bcl-Xl_42-CAF(®)09b vaccines in patients with locally advanced prostate cancer
por: Mørk, Sofie Kirial, et al.
Publicado: (2023)

T Cell Epitope Prediction and Its Application to Immunotherapy
por: Schaap-Johansen, Anna-Lisa, et al.
Publicado: (2021)

Adoptive cell therapy with tumor-infiltrating lymphocytes supported by checkpoint inhibition across multiple solid cancer types
por: Kverneland, Anders Handrup, et al.
Publicado: (2021)

MHC-based detection of antigen-specific CD8(+) T cell responses
por: Hadrup, Sine Reker, et al.
Publicado: (2010)

Comment on “5-Azacytidine Promotes an Inhibitory T-Cell Phenotype and Impairs Immune Mediated Antileukemic Activity”
por: Frøsig, Thomas Mørch, et al.
Publicado: (2015)

Evolution of MHC-based technologies used for detection of antigen-responsive T cells
por: Bentzen, Amalie Kai, et al.
Publicado: (2017)

T-cell-receptor cross-recognition and strategies to select safe T-cell receptors for clinical translation
por: Bentzen, Amalie Kai, et al.
Publicado: (2019)

High frequency of T cells specific for cryptic epitopes in melanoma patients
por: Andersen, Rikke Sick, et al.
Publicado: (2013)

The Immune System Strikes Back: Cellular Immune Responses against Indoleamine 2,3-dioxygenase
por: Sørensen, Rikke Bæk, et al.
Publicado: (2009)

An Analysis of Natural T Cell Responses to Predicted Tumor Neoepitopes
por: Bjerregaard, Anne-Mette, et al.
Publicado: (2017)

Corrigendum: An Analysis of Natural T Cell Responses to Predicted Tumor Neoepitopes
por: Bjerregaard, Anne-Mette, et al.
Publicado: (2018)

The anti-apoptotic members of the Bcl-2 family are attractive tumor-associated antigens
por: thor Straten, Per, et al.
Publicado: (2010)

T cell recognition of novel shared breast cancer antigens is frequently observed in peripheral blood of breast cancer patients
por: Viborg, Nadia, et al.
Publicado: (2019)

Fc-independent functions of anti-CTLA-4 antibodies contribute to anti-tumor efficacy
por: Sato, Yosuke, et al.
Publicado: (2022)

Qualitative Analysis of Tumor-Infiltrating Lymphocytes across Human Tumor Types Reveals a Higher Proportion of Bystander CD8(+) T Cells in Non-Melanoma Cancers Compared to Melanoma
por: Gokuldass, Aishwarya, et al.
Publicado: (2020)

Hyaluronidase Enhances Targeting of Hydrogel-Encapsulated Anti-CTLA-4 to Tumor Draining Lymph Nodes and Improves Anti-Tumor Efficacy
por: Harui, Airi, et al.
Publicado: (2022)

Thermosensitive hydrogel releasing nitric oxide donor and anti-CTLA-4 micelles for anti-tumor immunotherapy
por: Kim, Jihoon, et al.
Publicado: (2022)

Immune Cell Profiling of Peripheral Blood as Signature for Response During Checkpoint Inhibition Across Cancer Types
por: Araujo B. de Lima, Vinicius, et al.
Publicado: (2021)

CD8(+) T cells from patients with narcolepsy and healthy controls recognize hypocretin neuron-specific antigens
por: Pedersen, Natasja Wulff, et al.
Publicado: (2019)

BRAF inhibition improves tumor recognition by the immune system: Potential implications for combinatorial therapies against melanoma involving adoptive T-cell transfer
por: Donia, Marco, et al.
Publicado: (2012)

Highly efficient PD-1-targeted CRISPR-Cas9 for tumor-infiltrating lymphocyte-based adoptive T cell therapy
por: Chamberlain, Christopher Aled, et al.
Publicado: (2022)

Synergistic Effect of CTLA-4 Blockade and Cancer Chemotherapy in the Induction of Anti-Tumor Immunity
por: Lesterhuis, W. Joost, et al.
Publicado: (2013)

(64)Cu-DOTA-Anti-CTLA-4 mAb Enabled PET Visualization of CTLA-4 on the T-Cell Infiltrating Tumor Tissues
por: Higashikawa, Kei, et al.
Publicado: (2014)

The Availability of a Functional Tumor Targeting T-Cell Repertoire Determines the Anti-Tumor Efficiency of Combination Therapy with Anti-CTLA-4 and Anti-4-1BB Antibodies
por: Jensen, Benjamin A. H., et al.
Publicado: (2013)

Nanoliposome C6‐Ceramide in combination with anti‐CTLA4 antibody improves anti‐tumor immunity in hepatocellular cancer
por: Qi, Xiaoqiang, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_5tffdnnlf6d09c9fpc5nro9h7p